DJIA 17,706.06 -51.85 -0.29%
NASDAQ 4,995.29 -17.84 -0.36%
S&P 500 2,072.65 -4.77 -0.23%
market minute promo

Merck & Co., Inc. (NYSE: MRK)

57.56 -0.04 (-0.07%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

MRK $57.56 -0.07%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $57.94
Previous Close $57.60
Daily Range $57.52 - $58.33
52-Week Range $52.49 - $63.62
Market Cap $162.6B
P/E Ratio 15.04
Dividend (Yield) $1.80 (3.1%)
Ex-Dividend Date
Dividend Pay Date
06/11/15
07/08/15
Volume 3,576,549
Average Daily Volume 10,003,005
Current FY EPS $3.44

Sector

Healthcare

Industry

Drug Makers

Merck & Co., Inc. (MRK) Description

A global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of innovative products to improve human and animal health. Website: http://www.merck.com/

News & Commentary

Stocks to Watch in Hep-C Drugs

These are the top hep-C drugmakers vying for share in this multibillion-dollar market.

Dow Jones (DJIA) Today: Merck (MRK) Leads The Day Higher, E I Du Pont De Nemours & Company (DD) Lags

Premarket Biotech Digest: Gilead Files TAF NDA, Pristiq Goes Generic, Biocept Surges 7%

Dow Analyst Moves: MRK

Celldex's Rintega Phase III Study Recommended to Continue - Analyst Blog

Celldex's Rintega Phase III Study Recommended to Continue - Analyst Blog

Deforestation Impacting Pharmaceutical Industry

Stock Market News for June 30, 2015 - Market News

Has Johnson & Johnson’s Stock Peaked?

Noteworthy ETF Inflows: VHT, PFE, MRK, UNH

Interesting October Stock Options for MRK

Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regime

Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint

See More MRK News...

MRK's Top Competitors

MRK $57.56 (-0.07%)
Current stock: MRK
JNJ $98.50 (0.03%)
Current stock: JNJ
NVS $99.55 (1.05%)
Current stock: NVS
RHHBY $35.19 (0.13%)
Current stock: RHHBY